Geographical disparities in the prognosis of patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy: a large institution-based cohort study from an endemic area

Si-Ting Lin, Dong-Fang Meng, Qi Yang, Wei Wang, Li-Xia Peng, Li-Sheng Zheng, Yuan-Yuan Qiang, Yan Mei, Liang Xu, Chang-Zhi Li, Xing-Si Peng, Hao Hu, Yan-Hong Lang, Zhi-Jie Liu, Ming-Dian Wang, Hai-Feng Li, Bi-Jun Huang, Chao-Nan Qian, Rui Sun

ABSTRACT

Objectives Geographical disparities have been identified as a specific barrier to cancer screening and a cause of worse outcomes for patients with cancer. In the present study, our aim was to assess the influence of geographical disparities on the survival outcomes of patients with nasopharyngeal carcinoma (NPC) treated with intensity-modulated radiation therapy (IMRT).

Design Cohort study.

Setting Guangzhou, China.

Participants A total of 1002 adult patients with NPC (724 males and 278 females) who were classified by area of residence (rural or urban) received IMRT from 1 January 2010 to 31 December 2014, at Sun Yat-sen University Cancer Center. Following propensity score matching (PSM), 812 patients remained in the analysis.

Main outcome measures We used PSM to reduce the bias of variables associated with treatment effects and outcome prediction. Survival outcomes were estimated using the Kaplan-Meier method and compared by the log-rank test. Multivariate Cox regression was used to identify independent prognostic factors.

Results In the matched cohort, 812 patients remained in the analysis. Kaplan-Meier survival analysis revealed that the rural group was significantly associated with worse overall survival (OS, p<0.001), disease-free survival (DFS, p<0.001), locoregional relapse-free survival (LRRFS, p=0.003) and distant metastasis-free survival (DMFS, p<0.001). Multivariate Cox regression showed worse OS (HR=3.126; 95% CI 1.902 to 5.138; p<0.001), DFS (HR=2.579; 95% CI 1.815 to 3.665; p<0.001), LRRFS (HR=2.742; 95% CI 1.359 to 5.533; p=0.005) and DMFS (HR=2.461; 95% CI 1.574 to 3.850; p<0.001) for patients residing in rural areas.

Conclusions The survival outcomes of patients with NPC who received the same standardised treatment were significantly better in urban regions than in rural regions. By analysing the geographical disparities in outcomes for NPC, we can guide the formulation of healthcare policies.

Strengths and limitations of this study

- The study was based on 1002 adult patients with nasopharyngeal carcinoma (NPC) in an endemic area who were followed for 8 years.
- We defined residential areas by China’s household registration system, as done in previous literature.
- Geographical disparities, as one of the socioeconomic factors, have been identified as a specific barrier to cancer screening and a cause of worse outcomes for patients with NPC.
- The differences in outcomes for residency status were due to some socioeconomic factors rather than guideline-concordant cancer treatment.
- The main limitation of this analysis is its retrospective, single-institute nature, and prospective studies are needed to validate our results.

INTRODUCTION

Nasopharyngeal carcinoma (NPC) is a common type of head and neck cancer that originates from the nasopharyngeal epithelium and has highly aggressive characteristics and metastatic potential.1 NPC is an endemic cancer with a higher incidence in certain regions of southern China, Southeast Asia and Africa than elsewhere.2 In southern regions of China, particularly in Guangdong Province, it occurs in approximately 25–30 cases per 100,000 persons, which is 2.5 times higher than the incidence in other areas.2 Radiotherapy (RT) is the main treatment for NPC because NPC cells are more sensitive to radiation.3 The US National Comprehensive Cancer Network clinical practice guidelines recommend induction chemotherapy (IC)
followed by platinum-based concurrent chemoradiotherapy (CCRT) as the first-line treatment for advanced NPC cases. The survival outcomes have dramatically improved over the past three decades because of progress in the management of NPC, including more accurate stage development, the evolution of RT technology and the extensive application of chemotherapy.

Geographical disparities, a socioeconomic factor that has been defined as the physical distance to a service supply in rural/urban areas, have been identified as a specific barrier to cancer screening and a cause of worse outcomes for patients with cancer. In the USA, 19% of patients with cancer are from rural regions. Patients with cancer from rural areas have been shown to have a poorer prognosis than their urban counterparts, with vast disparities observed for colorectal, breast, lung, cervical and prostate cancers. In China, according to World Bank statistics, approximately 41% (576.61 million) of the Chinese population lived in rural regions in 2017. The Cancer Statistics in China, 2015, indicated that for all cancers combined, rural residents had a notably higher age-standardised (Segi population) mortality rate than urban residents (149.0 per 100,000 vs 109.5 per 100,000 for mortality). Chen et al also found substantial variation in the 5-year survival outcome estimate: rural patients with cancer have a much lower survival rate than their city counterparts (30.3% vs 42.8%). The geographical disparities appeared to be far more important than biological differences. These geographical disparities, at least in part, could be explained by the limited access to and utilisation of health services, the financial burden of cancer treatment, the lower levels of healthcare and the larger proportion of patients with late-stage cancer in rural and undeveloped regions in China.

Unfortunately, the survival differences between patients with NPC living in rural and urban areas have not been clearly demonstrated with a large institution-based cohort study in an endemic area. Therefore, whether rural and urban patients with NPC received the same standardised treatment and had different prognoses needs further exploration. In this study, our aim was to estimate the influence of geographical disparities on the survival outcomes of patients with NPC treated with intensity-modulated radiation therapy (IMRT).

**MATERIALS AND METHODS**

**Data collection**

In this retrospective cohort study, we used data from the Unionnet Digital Medical Record System (UDMRS) of Sun Yat-sen University Cancer Center (SYSUCC) from 1 January 2010 to 31 December 2014. The UDMRS records each patient’s name, medical record number, residency status, sex, age, smoking status, diagnosis, pathological classification, Epstein-Barr virus (EBV) DNA copy number, clinical staging, Karnofsky Performance Score (KPS), treatment modality and follow-up and clinical endpoints, as well as the name of the doctor. We used only the UDMRS to set up a retrospective cohort to investigate outcomes, and we did not ask the patients new questions.

The eligibility criteria of our study were as follows: (1) histologically confirmed NPC by biopsy of the nasopharynx; (2) no distant metastasis; (3) WHO pathology II/III; (4) nontherapeutic intervention; (5) no other tumour types or serious noncancerous illnesses; and (6) received radical IMRT during comprehensive treatment. A total of 1002 histologically confirmed patients with non-metastatic NPC were included in this criteria.

Our study was approved by the Clinical Research Ethics Committee of SYSUCC, and informed consent was obtained from all patients before treatment. All the methods were conducted according to approved guidelines in the present study.

**Diagnosis and treatment**

The routine diagnostic and staging workup included a complete medical history, physical examination, flexible fiberoptic nasopharyngoscopy, MRI of the nasopharyngeal and whole neck areas, chest radiography, abdominal sonography and whole-body bone scan, as well as positron emission tomography/computed tomography, if necessary. Molecular biomarkers of EBV-associated NPC were quantified, including the EBV DNA copy number, immunoglobulin A antibodies to EBV viral capsid antigen and EBV early antigen. All patients were restaged according to the seventh edition of the American Joint Committee on Cancer/Union for International Cancer Control staging system.

All patients were treated according to the principle of treatment for NPC at SYSUCC. The treatment modalities included RT alone, RT following IC (IC + RT), CCRT and CCRT following IC (IC + CCRT). All 1002 patients received radical IMRT at SYSUCC. The prescribed radiation doses were 60–72 Gy at 2.12–2.43 Gy/fraction to the planning target volume (PTVnx) of the primary gross tumour volume (GTVnx), 64–70 Gy to the PTVnd of the involved lymph nodes (GTVnd), 60–63 Gy to PTV1 of the high-risk clinical target volume (CTV1), and 50–56 Gy to PTV2 of the low-risk clinical target volume (CTV2). IC primarily consisted of cisplatin-based regimens: fluorouracil and cisplatin (PF), docetaxel and cisplatin (TP), gemcitabine plus cisplatin (GP) or docetaxel plus cisplatin and fluorouracil (TFP) every 3 weeks for 2–4 cycles. Concurrent chemotherapy was a weekly or 3-weekly cisplatin regimen.

**Follow-up and clinical endpoints**

Tumours were assessed with the use of flexible fiberoptic nasopharyngoscopy and MRI of the nasopharyngeal and whole neck areas at 1 week after the end of RT alone or CCRT. In the first 3 years of follow-up, all patients were evaluated every 3 months and thereafter every 6 months until death. All endpoints were assessed or confirmed by the attending physician. For suspected lesions, fine-needle aspiration or biopsy was necessary to confirm locoregional or distant disease progression.
The primary endpoint was overall survival (OS), which was the time from diagnosis to death from any cause. The secondary endpoints included disease-free survival (DFS), which was the time from diagnosis to disease progression or death from any cause; locoregional relapse-free survival (LRRFS), which was the time from diagnosis to local or regional recurrence; and distant metastasis-free survival (DMFS), which was the time from diagnosis to the first distant metastasis. Patients who failed to be followed up were censored at the date of the last follow-up. Of 1002 patients with NPC, 130 were lost to follow-up.

Explanatory variables
Based on the distribution of the population, China’s Registration Household (Hukou) System classifies individuals as having an agricultural (rural) or non-agricultural (urban) residency status. In our study, we categorised residential areas into two groups: rural areas (regions that are located outside of towns and cities, including countryside areas, villages and hamlets) and urban areas (areas with a high population density and an infrastructure of built environments, including cities, towns and suburban areas).

Statistical analysis
We used propensity score matching (PSM) to reduce the bias of variables associated with treatment effects and outcome prediction. Variables based on clinical practice were identified by logistic regression and introduced to generate a propensity score. A one-to-one nearest neighbour matching algorithm with a calliper of 0.2 and without replacement was used. We tested the differences between the rural group and urban group according to covariates by using the χ² test. Survival outcomes were estimated by using the Kaplan-Meier method and compared by the log-rank test. The multivariate Cox proportional hazards model was used to estimate HRs, 95% CIs and independent prognostic factors. We further carried out an interaction analysis to explore whether the prognostic value of residency status varied in the subgroups defined according to T classification, N classification, EBV DNA and treatment modality. The interaction analysis was conducted by means of a test of treatment-by-covariate interaction on the basis of the Cox proportional hazards model. All statistical tests were two sided, and p<0.05 was considered significant. All analyses were conducted using Statistical Package for Social Sciences V.22 (SPSS Inc, Chicago, Illinois, USA).

Patient and public involvement
The patients or the public were not involved in the design, conduct, reporting or dissemination of this specific study.

RESULTS
Patient baseline characteristics
Initially, 1002 adult patients with NPC (724 males and 278 females) who were classified by area of residence received IMRT from 1 January 2010 to 31 December, 2014, at SYSUCC. Following PSM, 812 patients remained in the analysis. In the matched cohort, the median age for the whole cohort was 45 years, and the male-to-female ratio was 2.46:1. There were 114 (14.04%) patients with stage I–II NPC and 698 (85.96%) patients with stage III–IVB NPC. Among 812 patients with NPC, 96 (11.82%) patients received RT alone, 57 (7.02%) patients received IC + RT, 319 (39.29%) patients received CCRT and 340 (41.87%) patients received IC + CCRT. The two groups had similar treatment modalities (p=0.678). The host-related and tumour-related factors (sex, age, smoking, histology, T classification, N classification, clinical stage, EBV DNA, treatment modality and KPS) were well balanced between the rural and urban groups. The baseline characteristics are summarised in table 1.

Long-term outcome analysis
The median follow-up time for the whole cohort was 58.0 months (range 1.0–98.0). During the follow-up period, 103 (25.37%) of 406 patients in the rural group and 45 (11.08%) of 406 patients in the urban group experienced disease progression. Eighty-three of 812 patients died: 62 (15.27%) patients in the rural group and 21 (5.17%) patients in the urban group. Patients with rural versus urban residences had 5-year OS, DFS, LRRFS and DMFS rates of 84.73% versus 94.83% (344 of 406 vs 385 of 406, p<0.001), 74.63% versus 88.92% (303 of 406 vs 361 of 406, p<0.001), 93.35% versus 97.78% (379 of 406 vs 397 of 406, p=0.002) and 84.73% versus 93.1% (344 of 406 vs 378 of 406, p<0.001), respectively. Kaplan-Meier survival analysis revealed that the rural group was significantly associated with worse OS (p<0.001), DFS (p<0.001), LRRFS (p=0.003) and DMFS (p<0.001, figure 1).

Prognostic factors for patients with NPC with rural/urban residences
Multivariate analysis was performed to adjust for potential prognostic factors, including sex, smoking, N category, EBV DNA, KPS, area of residence and treatment modality. The results of the multivariate analysis using the standard Cox proportional hazards model are shown in table 2. The multivariate Cox regression results showed worse OS (HR=3.126; 95% CI 1.902 to 5.138; p<0.001), DFS (HR=2.579; 95% CI 1.815 to 3.665; p<0.001), LRRFS (HR=2.742; 95% CI 1.359 to 5.533; p=0.005) and DMFS (HR=2.461; 95% CI 1.574 to 3.850; p<0.001) for patients residing in rural areas. In addition, EBV DNA was an independent prognostic factor for OS (HR=3.031; 95% CI 1.95 to 4.723; p<0.001), DFS (HR=2.733; 95% CI 1.955 to 3.818; p<0.001) and DMFS (HR=3.657; 95% CI 2.339 to 5.718; p<0.001). These results indicated that residency status represented a valuable independent prognostic factor for patients with NPC.

Subgroup analysis
To further assess the prognostic value of residency status, the patients with NPC were stratified into subgroups based on T classification (categorised as T1–2 or T3–4), N classification (categorised as N0–1 or N2–3), clinical stage (categorised as stage I–II or III–IVB), EBV DNA
| Characteristics          | Unmatched (n=1002) | Matched (n=812) |
|-------------------------|--------------------|-----------------|
|                         | Rural No (%) (n=421) | Urban No (%) (n=581) | P value* | Rural No (%) (n=406) | Urban No (%) (n=406) | P value* |
| **Sex**                 |                    |                  |           |                    |                  |           |
| Male                    | 300 (71.26)        | 424 (72.98)      | 0.549     | 292 (71.92)        | 285 (70.20)      | 0.588     |
| Female                  | 121 (28.74)        | 157 (27.02)      |           | 114 (28.08)        | 121 (29.80)      |           |
| **Age (years)**         | 0.11               |                  |           | 0.706               |                  |           |
| Median                  | 45                 | 46               |           | 45                 | 45               |           |
| Range                   | 18–69              | 19–70            |           | 18–69              | 19–70            |           |
| **Smoking status**      | 0.064              |                  |           | 0.714               |                  |           |
| No                      | 267 (63.42)        | 401 (69.02)      |           | 259 (63.79)        | 264 (65.02)      |           |
| Yes                     | 154 (36.58)        | 180 (30.98)      |           | 147 (36.21)        | 142 (34.98)      |           |
| **Histology**           | 0.646              |                  |           | 0.483               |                  |           |
| WHO type                |                    |                  |           |                    |                  |           |
| II                      | 15 (3.56)          | 24 (4.13)        |           | 15 (3.69)          | 19 (4.68)        |           |
| III                     | 406 (96.44)        | 557 (95.87)      |           | 391 (96.31)        | 387 (95.32)      |           |
| **T classification†**   | 0.006              |                  |           | 0.068               |                  |           |
| T1                      | 40 (9.50)          | 52 (8.95)        |           | 40 (9.85)          | 30 (7.39)        |           |
| T2                      | 52 (12.35)         | 105 (18.07)      |           | 51 (12.56)         | 77 (18.97)       |           |
| T3                      | 210 (49.88)        | 307 (52.84)      |           | 204 (50.25)        | 193 (47.54)      |           |
| T4                      | 119 (28.27)        | 117 (20.14)      |           | 111 (27.34)        | 106 (26.11)      |           |
| **N classification†**   | 0.072              |                  |           | 0.804               |                  |           |
| N0                      | 44 (10.45)         | 80 (13.77)       |           | 43 (10.59)         | 52 (12.81)       |           |
| N1                      | 170 (40.38)        | 240 (41.31)      |           | 168 (41.38)        | 162 (39.90)      |           |
| N2                      | 158 (37.53)        | 218 (37.52)      |           | 154 (37.93)        | 152 (37.44)      |           |
| N3                      | 49 (11.64)         | 43 (7.40)        |           | 41 (10.10)         | 40 (9.85)        |           |
| **Clinical stage**      | 0.005              |                  |           | 0.718               |                  |           |
| I                       | 11 (2.61)          | 20 (3.44)        |           | 11 (2.71)          | 10 (2.46)        |           |
| II                      | 40 (9.50)          | 74 (12.74)       |           | 40 (9.85)          | 53 (13.05)       |           |
| III                     | 214 (50.83)        | 335 (57.66)      |           | 211 (51.97)        | 206 (50.74)      |           |
| IVA                     | 106 (26.25)        | 109 (18.76)      |           | 102 (25.12)        | 97 (23.89)       |           |
| IVB                     | 50 (11.88)         | 43 (7.40)        |           | 42 (10.34)         | 40 (9.85)        |           |
| EBV DNA (copies/mL)     | <0.001             |                  |           | 0.715               |                  |           |
| <3000                   | 258 (61.28)        | 417 (71.77)      |           | 257 (63.30)        | 262 (64.53)      |           |
| ≥3000                   | 163 (38.72)        | 164 (28.23)      |           | 149 (36.70)        | 144 (35.47)      |           |
| **Characteristic**      |                    |                  |           |                    |                  |           |
|                         | Unmatched (n=1002) | Matched (n=812) |
|                         | Area of residence  | Area of residence |
|                         | Rural No.(%) (n=421) | Urban No.(%) (n=581) | P value* | Rural No.(%) (n=406) | Urban No.(%) (n=406) | P value* |
| Treatment modality      | 0.367              |                  |           | 0.678               |                  |           |
| RT alone                |                    |                  |           |                    |                  |           |
| IC + RT                 | 44 (10.45)         | 75 (12.91)       |           | 43 (10.59)         | 53 (13.05)       |           |
| CCRT                    | 31 (7.36)          | 31 (5.34)        |           | 31 (7.64)          | 26 (6.40)        |           |
| IC + CCRT               | 166 (39.43)        | 237 (40.79)      |           | 161 (39.66)        | 158 (38.92)      |           |
|                         | 180 (42.76)        | 238 (40.96)      |           | 171 (42.12)        | 169 (41.63)      |           |

Continued
Subgroup analysis also revealed that the patients residing in rural areas had worse OS, DFS and DMFS than their urban counterparts (figure 2). However, no significant difference in LRRFS was observed in the T1–2 subgroup (p=0.470), N0–1 subgroup (p=0.167), stage I–II subgroup (p=0.348), low EBV DNA levels subgroup (p=0.093), and treatment without IC subgroup (p=0.166). The stratification analysis demonstrated that the mortality risk was more pronounced in patients with advanced NPC who lived in rural areas, had higher EBV DNA copy numbers and were treated without IC.

**DISCUSSION**

Numerous previous studies have reported that rural patients with cancer have worse outcomes than their urban counterparts. However, no prior studies have systematically compared the geographical distribution...
and survival outcomes for rural versus urban patients with NPC. Our comprehensive analysis examined 1002 patients with NPC, and 812 eligible patients were uniformly staged, treated and followed up. To our knowledge, this retrospective study was the first to identify that rural and urban patients with NPC who received IMRT have significantly different prognoses and that there was a statistically significant risk of mortality for patients with NPC in rural regions compared with those in urban regions. Therefore, the findings of previous analyses were reinforced by the observation of a significant difference in clinical prognosis between rural and urban patients with NPC in our study.

This finding suggested that previously observed differences in outcomes for residency status were due to some socioeconomic factors rather than clinical characteristics of the disease and treatment. Several theories have been proposed to explain these findings, including geographic distribution, travel distance/time to healthcare services, low socioeconomic status, low income, lower educational level and lack of publicly financed health insurance coverage.25 26

Access to healthcare services could be characterised by geographic factors, such as region, travel distance and time.27 Oncology resources for providers in rural communities are scarce; approximately one-fifth of the US population lives in rural areas, but only 3% of medical oncologists work in rural areas.28 The situation is similar in China, where every 1000 Chinese rural residents have access to 1.59 practising physicians, which is much lower than the number of physicians for every 1000 urban residents, which is 3.92.29 Lin et al evaluated the relationship between the density of oncologists and the receipt of adjuvant chemotherapy in patients with stage III colon cancer. They found that patients who lived in rural areas with a lower oncologist density were less likely to receive adjuvant chemotherapy.9 Studies have demonstrated that geographic access to care is a potentially modifiable factor that decreases the utilisation of adjuvant chemotherapy.9 In cancer diagnosis, a greater availability of oncologists

| Table 2 Multivariate analysis for prognostic factors in the 812 patients with NPC |
|-----------------------------------------------|
| **Endpoints** | HR (95% CI) | P value |
| OS | | |
| Sex | | 0.02 |
| Female | Reference | |
| Male | 2.168 (1.164 to 4.039) | |
| EBV DNA (copies/mL) | <0.001 |
| <3000 | Reference | |
| ≥3000 | 3.031 (1.945 to 4.723) | |
| KPS | 0.017 |
| ≥90 | Reference | |
| <90 | 4.657 (1.425 to 15.222) | |
| Area of residence | <0.001 |
| Urban | Reference | |
| Rural | 3.126 (1.902 to 5.138) | |
| DFS | 0.015 |
| Smoking | | |
| No | Reference | |
| Yes | 1.495 (1.081 to 2.068) | |
| N category | 0.01 |
| N0–1 | Reference | |
| N2–3 | 1.555 (1.110 to 2.177) | |
| EBV DNA (copies/mL) | <0.001 |
| <3000 | Reference | |
| ≥3000 | 2.733 (1.955 to 3.818) | |
| Area of residence | <0.001 |
| Urban | Reference | |
| Rural | 2.579 (1.815 to 3.665) | |
| LRRFS | 0.001 |
| KPS | | |
| ≥90 | Reference | |
| <90 | 12.552 (3.001 to 52.508) | |
| Area of residence | 0.005 |
| Urban | Reference | |
| Rural | 2.742 (1.359 to 5.533) | |
| DMFS | 0.003 |
| Smoking | | |
| No | Reference | |
| Yes | 1.875 (1.239 to 2.838) | |
| N category | <0.001 |
| N0–1 | Reference | |
| N2–3 | 2.543 (1.601 to 4.040) | |
| EBV DNA (copies/mL) | <0.001 |
| <3000 | Reference | |
| ≥3000 | 3.657 (2.339 to 5.718) | |

P values were calculated using a Cox proportional hazard regression model with backward elimination.

DFS, disease-free survival; DMFS, distant metastasis-free survival; EBV, Epstein-Barr virus; IC, induction chemotherapy; KPS, Karnofsky Performance Score; LRRFS, locoregional relapse-free survival; OS, overall survival.
seems to be related to early diagnosis and better prognosis. However, rural residents often seek treatment for NPC that is considered to lack access to cancer screening, diagnosis and therapy. Effective population screening can improve treatment outcomes by identifying early stages of the disease. Plasma EBV DNA detection and fiberoptic nasopharyngoscopy are useful for NPC screening. Unlike plasma EBV DNA testing, however, fiberoptic nasopharyngoscopy requires the expertise of oncologists. Rural residency is associated with a smaller number of NPC specialists, medical oncologists and radiation therapists. Even the patients with NPC who resided in rural regions and received IMRT also had unmet supportive care needs compared with urban residents. Therefore, the significantly fewer providers of screening and adjuvant therapy for NPC in rural regions may affect the availability of their services, which leads to worse prognosis for patients with advanced NPC who seek treatment.

For physician workforces that are not widely geographically distributed, access to care may be limited, which can be measured by the travel distance and travel time. Rural residents with cancer are affected by increased travel distances to receive treatment, adding considerable time and economic burdens to treatment. Laura-Mae found that fewer than 50% of rural patients with colorectal cancer had a medical or radiation oncologist within 30 miles. The increased transportation barriers to healthcare can result in low levels of standard care. Other studies have analysed the complicated relationship between travel distance and nursing care among patients with cervical cancer. In rural areas, patients with cancer who lived ≥15 miles from the nearest facility were less likely to receive primary surgery compared with the national average. A retrospective cohort study identified that patients diagnosed with stage III colon cancer who travelled 50 to 250 miles had a significantly decreased likelihood of receiving adjuvant chemotherapy, regardless of insurance status.

As a principal health risk factor in any geographical location, poverty is more prevalent and consistent in rural regions and is often associated with increased rates of cancer. According to United States Census Bureau, approximately 16.4% of the rural population lives in poverty compared to 12.9% of the urban population in 2017. There are wide gaps in cancer death rates among low-income, medium-income and high-income counties. A study by O’Connor et al assessed the relationship between US county income levels across the USA and cancer death rates. The cancer death rate of low-income residents who lived in rural areas was 229.7 per 100 000 person-years in low-income counties, compared with 204.9 and 185.9 per 100 000 person-years in medium-income and high-income counties, respectively. In China, 91.1% of households in rural patients with end-of-life cancer were below the poverty line compared with 84.1% of urban patients. Rural patients with cancer continued to suffer long-term financial burden and increased out-of-pocket costs.
expenses. Moreover, they are also less likely to meet healthcare needs and less likely to receive preventive and therapeutic healthcare.

These findings have implications that challenge the current policies of the primary healthcare system in China. There are three main types of publicly financed insurance: the Urban Employee Basic Medical Insurance (UEBMI) for urban residents and retired employees, the Urban Resident Basic Medical Insurance (URBMI) for urban residents (children, students, elderly without employment and unemployed persons) and the New Rural Cooperative Medical Scheme (NRCSMS) for rural residents. Although China has made remarkable achievements in improving its primary healthcare system, the system still faces some challenges, such as ageing and turnover of village doctors, healthcare inequity between rural and urban regions, inadequate qualifications and education of its workforce in rural areas, difficulty obtaining adequate medical services and quality of care. One study illustrated that NRCSMS and URBMI participants have worse self-reported health status, physical functions and psychological well-being than their UEBMI counterparts. In addition, a study indicated that patients in the poorest areas cannot even afford outpatient care expenses after reimbursement from healthcare insurance. Rural residents were less likely to buy private health insurance, widening the disparities in access to healthcare and preventive services. In conclusion, a major challenge to the objective of providing equal healthcare for all is unequal insurance schemes in rural and urban areas. To address geographic disparities, the Chinese government should pay more attention to the equality of the healthcare system while providing more funding for NRCSMS to ensure that rural residents in need could benefit from medical service utilisation.

Limitations

We acknowledge that our study has several inherent limitations seen in observational studies. First, the main limitation of this analysis is its retrospective and single-institute nature, and prospective studies are needed to validate our results. Second, although our statistical results explained geographic distribution and clinical prognostic factors, other socioeconomic factors, such as education level and household income, might affect the results. For instance, rural patients who received higher education may also be more likely to have a better understanding of disease and have a greater self-care ability. Third, travel distance may result in barriers to cancer treatment and is different between rural and urban patients with NPC. However, the influence of travel distance on patients in choosing medical institutions is uncertain. Moreover, a multicentre population-based cross-sectional survey is needed to comprehensively evaluate the geographical disparities in survival outcomes for patients with NPC treated with IMRT.

CONCLUSIONS

This study shows that the survival outcomes of patients with NPC who receive the same standardised treatment are significantly better in urban regions than in rural regions. This finding further demonstrates the disparities in access to healthcare for rural and urban residents in China. These disparities adversely affect the outcomes of patients with NPC in rural regions. Overall, rural residency is an important predictor of access to healthcare for the general population of patients with cancer. By analysing the geographic disparities in outcomes for NPC, we can guide the formulation of healthcare policies.

Author affiliations

1State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China
2Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
3Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China
4Department of Oncology, The First People’s Hospital of Kashi, Kashi, China
5Ningxia Key Laboratory for Cerebrocranial Disease, Ningxia Medical University, Yinchuan, Ningxia, China
6Institute of Gastroenterology, Sun Yat-sen University Sixth Affiliated Hospital, Guangzhou, Guangdong, China
7Department of Traditional Chinese Medicine, Sun Yat-sen University First Affiliated Hospital, Guangzhou, Guangdong, China

Contributors All authors were involved in the conception, design and implementation of the project. X-SP, HH, L-XP, L-SZ, Y-QY and Y-HL participated in the data collection. D-FM, S-TL, DY and WW analysed and interpreted the data, and drafted the manuscript, with YM, LX, Z-JL, M-DW, H-FL and C-ZL providing critical input at all stages. RS, B-JH and C-NQ drafted and revised the manuscript. All authors approved the final version of the manuscript.

Funding This work was supported by grants from the National Natural Science Foundation of China (No. 81872384, No. 81 672 872 and No. 81 472 386 to C.Q., No. 81 972 785, No. 81 773 162, No. 81 572 901, No. 31 170 151 to B.H.), the Science and Technology Planning Project of Guangdong Province, China (No. 2013B021800065 to R.S., No. 2014A020209024 to B.H.), and the Provincial Natural Science Foundation of Guangdong, China (No. 2016A030311011 to C.Q., No. 2017A030313866 to B.H.).

Competing interests None declared.

Patient consent for publication Parental/guardian consent obtained.

Ethics approval This study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or similar ethical standards.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement The data are not available for public access because of patient privacy concerns but are available from the corresponding author on reasonable request approved by the institutional review boards of Sun Yat-sen University Cancer Center.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD

Dong-Fang Meng http://orcid.org/0000-0001-9840-1133
REFERENCES

1. Wei K-R, Zheng R-S, Zhang S-W, et al. Nasopharyngeal carcinoma incidence and mortality in China, 2013. Chin J Cancer 2017;36:90.

2. Chen YP, Chan ATC, QT L, et al. Nasopharyngeal carcinoma. Lancet 2019.

3. Goo JI, Richmon JD, Agrawal N, et al. AHNS Series - Do you know your guidelines? Principles of treatment for nasopharyngeal cancer: A review of the National Comprehensive Cancer Network guidelines. Head Neck 2017;39:201–5.

4. Meng D-F, Sun R, Peng L-X, et al. A comparison of Weekly versus 3-weekly cisplatin chemotherapy at diagnosis chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma using intensity modulated radiation therapy: a matched study. J Cancer 2018;9:92–9.

5. Colevas AD, Yom SS, Pfister DG, et al. NCCN guidelines insights: head and neck cancers, version 1.2018. J Natl Compr Canc Netw 2018;16:479–90.

6. Gill A, Givi B, Moore MG. AHNS Series - Do you know your guidelines?: Assessment and management of malnutrition in patients with head and neck cancer. Review of the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines). Head Neck 2019;41:577–83.

7. Zhang Y, Chen L, Hu G-Q, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med 2019;381:1124–35.

8. Chan S-C, Yeh C-H, Yen T-C, et al. Clinical utility of simultaneous whole-body 18F-FDG PET/MRI as a single-step imaging modality in the staging of primary nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging 2018;45:1297–308.

9. Lin CC, Bruinooge SS, Kirkwood MK, et al. Association between geographic access to cancer care, insurance, and receipt of chemotherapy: geographic distribution of oncologists and travel distance. J Clin Oncol 2015;33:3177–85.

10. Massarweh NN, Chiang Y-J, King Y, et al. Association between travel distance and metastatic disease at diagnosis among patients with colon cancer. J Clin Oncol 2014;32:942–8.

11. Unger JM, Moseley A, Symington B, et al. Geographic distribution and survival outcomes for rural patients with cancer treated in clinical trials. JAMA Netw Open 2018;1:e181235.

12. van Die J, MSJAMA vanDJ. MSJAMA, where we live: health care in rural vs urban America. JAMA 2002;287:108.

13. Johnson AM, Hines RB, Johnson JA, et al. Treatment and survival disparities in lung cancer: the effect of social environment and place of residence. Lung Cancer 2014;83:401–7.

14. Zhan FB, Lin Y. Racial/Ethnic, socioeconomic, and geographic disparities of cervical cancer advanced-stage diagnosis in Texas. Womens Health Issues 2014;24:519–27.

15. Wan N, Zhan FB, Cai Z. Socioeconomic disparities in prostate cancer mortality and the impact of geographic scale. South Med J 2011;104:553–9.

16. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115–32.

17. Beckfield J, Olafsdottir S. Health inequalities in global context. Am Behav Sci 2013;57:1014–39.

18. Leng A, Jing J, Nicholas S, et al. Geographical disparities in treatment and health care costs for end-of-life cancer patients in China: a retrospective study. BMC Cancer 2019;19:39.

19. Wang Q, Jiao J. Health disparity and cancer health disparity in China. Asia Pac J Oncol Nurs 2016;3:335–43.

20. Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471–4.

21. Song Q, Smith JP. Hukou system, mechanisms, and health stratification across the life course in rural and urban China. Health Place 2019;58:102150.

22. Peng X. China’s demographic history and future challenges. Science 2011;333:581–7.

23. Aboagye JK, Kaiser HE, Hayanga AJ. Rural-Urban differences in access to specialist intensity-modulated radiotherapy in the United States: a physician workforce issue. JAMA Surg 2014;149:537–43.

24. Williams F, Thompson E. Disparity in breast cancer late stage at diagnosis in Missouri: does rural versus urban residence matter? J Racial Ethn Health Disparities 2016;3:233–9.

25. De Vogli R, Gimeno D, Kivimaki M. Socioeconomic inequalities in health in 22 European countries. N Engl J Med 2008;359:1290.

26. Berkman L, Epstein AM. Beyond health care--socioeconomic status and health. N Engl J Med 2008;358:2509–10.

27. Omega T, Duell EJ, Shi X, et al. Geographic access to cancer care in the U.S. Cancer 2008;112:909–18.

28. Kirkwood MK, Bruinooge SS, Goldstein MA, et al. Enhancing the American Society of clinical oncology workforce information system with geographic distribution of oncologists and comparison of data sources for the number of practicing oncologists. J Oncol Pract 2014;10:32–8.

29. Yearbook C S. National Bureau of statistics of China[J]. Chinese Statistical Yearbook, 2012.

30. Ananthakrishnan AN, Hoffmann RG, Saeian K. Higher physician density is associated with lower incidence of late-stage colorectal cancer. J Gen Intern Med 2010;25:1164–71.

31. McDowell LJ, Rock K, Xu W, et al. Long-term late toxicity, quality of life, and emotional distress in patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2018;102:340–52.

32. Baldwin L-M, Cai Y, Larson EH, et al. Access to cancer services for rural colorectal cancer patients. J Rural Health 2008;24:390–9.

33. Spees LF, Wheeler SB, Varia M, et al. Evaluating the urban-rural paradox: the complicated relationship between distance and the receipt of guideline-concordant care among cervical cancer patients. Gynecol Oncol 2019;152:112–8.

34. Blumenthal SJ, Kagen J. MSJAMA. The effects of socioeconomic status on health in rural and urban America. JAMA 2002;287:109.

35. O’Connor JM, Sedghi T, Dhodapkar M, et al. Factors associated with cancer disparities among low-, medium-, and high-income us counties. JAMA Netw Open 2018;1:e183146.

36. Leng A, Jing J, Nicholas S, et al. Catastrophic health expenditure of cancer patients at the end-of-life: a retrospective observational study in China. BMC Palliat Care 2019;18:43.

37. Heady HR. MSJAMA. A delicate balance: the economics of rural health care delivery. JAMA 2002;287:110.

38. Sun Y, Gregersen H, Yuan W. Chinese health care system and clinical epidemiology. Clin Epidemiol 2017;9:167–78.

39. Liu X, Wang H, Liu K. Outcome-based health equity across different social health insurance schemes for the elderly in China. BMC Health Serv Res 2016;16:9.

40. Yuan S, Rehnberg C, Sun X, et al. Income related inequalities in new cooperative medical scheme: a five-year empirical study of Junan County in China. Int J Equity Health 2014;13:38.